Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adocia S.A. (ADOC.PA)
Lyon, FR
Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its unique BioChaperone technological platform, specifically designed to boost the performance of these therapeutic proteins. Its robust clinical pipeline showcases several advanced insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid-acting versions of insulin lispro. Other key candidates are BioChaperone Combo, a blend of long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous human glucagon formulation for managing hypoglycemia. M1Pram, a derivative combining insulin glargine and pramlintide, is also under clinical investigation. In its earlier preclinical development phases, Adocia is advancing bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose pairing of insulin glargine with a GLP-1 receptor analogue. The preclinical portfolio also extends to multihormonal therapies for obesity, featuring BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple combination of pramlintide, glucagon, and exenatide. Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. to facilitate the development and commercialization of BioChaperone Lispro and BioChaperone Combo in China, as well as selected markets in Asia and the Middle East. The company was founded in 2005 and is headquartered in Lyon, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.30% | +1.11% | +1.11% | -26.36% | -39.01% | -26.36% | +33.71% | +21.98% | -43.74% | -90.87% | -68.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-84.2% Q4'25: -238.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-41.7% Q4'25: +58.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-405.5% Q4'25: -368.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,076.7% Q4'25: +959.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +353.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+26.8% Q4'25: +47.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.58× Q4'25: -0.33× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.59M
est: 8.93M (-37.4%)
|
704.0K
est: 5.84M (-88.0%)
|
36.94M
est: 36.90M (+0.1%)
|
22.49M
est: 22.40M (+0.4%)
|
19.47M
est: 28.80M (-32.4%)
|
47.39M
est: 44.05M (+7.6%)
|
2.14M
est: 23.04M (-90.7%)
|
841.0K
est: 27.57M (-96.9%)
|
1.44M
est: 1.44M (+0.0%)
|
11.45M
est: 30.95M (-63.0%)
|
2.15M
est: 3.59M (-40.2%)
|
9.32M
est: 9.32M (+0.0%)
|
1.48M
est: 1.48M (+0.0%)
|
10.07M
5.24M – 14.89M
+582.5% YoY
|
43.90M
40.80M – 47.00M
+336.1% YoY
|
10.23M
6.49M – 13.96M
-76.7% YoY
|
26.24M
16.65M – 35.83M
+156.6% YoY
|
35.92M
22.79M – 49.06M
+36.9% YoY
|
| EBITDA |
-3.94M
est: -8.47M (+53.5%)
|
-16.17M
est: -2.51M (-543.5%)
|
12.73M
est: -84.79M (+115.0%)
|
-6.98M
est: 13.02M (-153.6%)
|
-7.17M
est: -7.73M (+7.2%)
|
6.58M
est: -9.78M (+167.2%)
|
-19.99M
est: 8.57M (-333.2%)
|
-19.95M
est: -21.90M (+8.9%)
|
-24.10M
est: -36.97M (+34.8%)
|
-12.34M
est: -148.54M (+91.7%)
|
-19.35M
est: -3.41M (-468.0%)
|
-6.91M
est: -550.07M (+98.7%)
|
-15.37M
est: -1.40M (-998.7%)
|
-9.55M
-14.12M – -4.97M
-582.5% YoY
|
-41.63M
-44.56M – -38.69M
-336.1% YoY
|
-9.70M
-13.24M – -6.15M
+76.7% YoY
|
-24.88M
-33.98M – -15.78M
-156.6% YoY
|
-34.06M
-46.52M – -21.61M
-36.9% YoY
|
| EBIT |
-4.19M
est: -8.56M (+51.1%)
|
-16.57M
est: -2.81M (-488.8%)
|
12.26M
est: -91.52M (+113.4%)
|
-7.74M
est: 8.64M (-189.7%)
|
-8.41M
est: -9.50M (+11.5%)
|
11.91M
est: -10.62M (+212.1%)
|
-21.15M
est: 5.53M (-482.3%)
|
-21.23M
est: -24.71M (+14.1%)
|
-25.12M
est: -41.72M (+39.8%)
|
-12.90M
est: -167.61M (+92.3%)
|
-19.85M
est: -3.45M (-476.2%)
|
-7.40M
est: -620.70M (+98.8%)
|
-15.88M
est: -1.41M (-1,022.9%)
|
-9.65M
-14.28M – -5.03M
-582.5% YoY
|
-42.09M
-45.06M – -39.12M
-336.1% YoY
|
-9.80M
-13.39M – -6.22M
+76.7% YoY
|
-25.16M
-34.36M – -15.96M
-156.6% YoY
|
-34.45M
-47.04M – -21.85M
-36.9% YoY
|
| Net Income |
-4.29M
est: -20.04M (+78.6%)
|
-20.72M
est: -2.81M (-638.0%)
|
12.55M
est: -110.47M (+111.4%)
|
-7.89M
est: 10.73M (-173.6%)
|
-8.55M
est: -9.37M (+8.7%)
|
7.62M
est: -11.10M (+168.6%)
|
-18.60M
est: 4.34M (-528.7%)
|
-23.32M
est: -20.87M (-11.7%)
|
-22.75M
est: -35.25M (+35.4%)
|
-6.90M
est: -20.55M (+66.4%)
|
-21.16M
est: -20.72M (-2.2%)
|
-9.32M
est: -9.71M (+4.0%)
|
-16.59M
est: -16.59M (+0.0%)
|
3.98M
-89.09M – 40.55M
+124.0% YoY
|
7.85M
4.58M – 11.12M
+97.5% YoY
|
-12.46M
-18.38M – -6.54M
-258.7% YoY
|
8.81M
4.62M – 12.99M
+170.7% YoY
|
38.43M
20.17M – 56.70M
+336.4% YoY
|
| SGA |
6.62M
est: 5.51M (+20.1%)
|
8.32M
est: 58.9K (+14,026.8%)
|
20.12M
est: 3.32M (+506.5%)
|
19.07M
est: 5.26M (+262.8%)
|
19.02M
est: 8.87M (+114.3%)
|
25.63M
est: 281.7K (+8,999.3%)
|
13.15M
est: 315.2K (+4,071.4%)
|
—
est: 263.7K (-100.0%)
|
—
est: 445.2K (-100.0%)
|
—
est: 1.79M (-100.0%)
|
5.48M
est: 4.88M (+12.4%)
|
5.00M
est: 12.65M (-60.5%)
|
5.46M
est: 2.00M (+172.7%)
|
13.66M
7.12M – 20.20M
+582.5% YoY
|
59.57M
55.36M – 63.77M
+336.1% YoY
|
13.88M
8.80M – 18.95M
-76.7% YoY
|
35.61M
22.59M – 48.62M
+156.6% YoY
|
48.75M
30.92M – 66.57M
+36.9% YoY
|
| EPS |
-0.70
est: -1.30 (+46.0%)
|
-3.33
est: -1.16 (-186.4%)
|
1.90
est: 0.37 (+408.9%)
|
-1.20
est: -1.00 (-20.2%)
|
-1.25
est: -0.74 (-68.5%)
|
1.00
est: 0.05 (+1,900.6%)
|
-2.68
est: -0.90 (-197.8%)
|
-3.34
est: -3.10 (-7.7%)
|
-3.22
est: -2.28 (-41.2%)
|
-0.86
est: -1.82 (+52.6%)
|
-1.91
est: -1.51 (-26.1%)
|
-0.60
est: 2.04 (-129.4%)
|
-0.85
est: -0.96 (+11.5%)
|
-0.66
-4.54 – 2.07
+31.6% YoY
|
0.40
0.23 – 0.57
+160.9% YoY
|
-0.64
-0.94 – -0.33
-258.7% YoY
|
0.45
0.24 – 0.66
+170.7% YoY
|
1.96
1.03 – 2.89
+336.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Olivier Soula | Co-Founder, Chief Executive Officer & Director | 300.0K | male |
| David Duracher | Head of the Pharmaceutical Development & Physical Chemistry Departments and Project Manager | — | — |
| Geraldine Favre Soula | Director of Human Resources | — | female |
| Grégory Meiffren | Head of the Biology Department & Project Manager | — | — |
| Jeremy Benattar | Marketing & Strategy Director | — | — |
| Mathieu-William Gilbert | Chief Operating Officer & Chief Financial Officer | — | male |
| Bertrand Alluis | Head of the Analysis Department and Project Manager | — | — |
| Richard Charvet | Head of Chemistry Department & Project Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADOC.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
